statistiche ricercatore

Continente	#
NA - Nord America	986
AS - Asia	366
EU - Europa	290
SA - Sud America	70
AF - Africa	16
Continente sconosciuto - Info sul continente non disponibili	8
OC - Oceania	1
Totale	1.737

Nazione	#
US - Stati Uniti d'America	971
SG - Singapore	115
IT - Italia	76
CN - Cina	61
BR - Brasile	49
VN - Vietnam	46
GB - Regno Unito	43
BD - Bangladesh	42
HK - Hong Kong	41
DE - Germania	39
SE - Svezia	34
FI - Finlandia	22
IE - Irlanda	18
RU - Federazione Russa	18
IN - India	13
FR - Francia	11
CA - Canada	8
ID - Indonesia	8
KR - Corea	7
AR - Argentina	6
BG - Bulgaria	6
JP - Giappone	6
PL - Polonia	6
ZA - Sudafrica	5
CO - Colombia	4
EC - Ecuador	4
IQ - Iraq	4
MX - Messico	4
MY - Malesia	4
PK - Pakistan	4
TR - Turchia	4
BE - Belgio	3
MA - Marocco	3
NL - Olanda	3
AZ - Azerbaigian	2
BO - Bolivia	2
DZ - Algeria	2
KE - Kenya	2
LT - Lituania	2
SI - Slovenia	2
SV - El Salvador	2
TN - Tunisia	2
UY - Uruguay	2
VE - Venezuela	2
AT - Austria	1
BW - Botswana	1
ES - Italia	1
GR - Grecia	1
HR - Croazia	1
HU - Ungheria	1
JM - Giamaica	1
KG - Kirghizistan	1
KZ - Kazakistan	1
LB - Libano	1
MD - Moldavia	1
ML - Mali	1
MN - Mongolia	1
NZ - Nuova Zelanda	1
PE - Perù	1
PH - Filippine	1
PS - Palestinian Territory	1
QA - Qatar	1
SA - Arabia Saudita	1
TH - Thailandia	1
UA - Ucraina	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	1.730

Nome	#
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis	359
Brca detection rate in an italian cohort of luminal early-onset and triple-negative breast cancer patients without family history: When biology overcomes genealogy	324
Lifestyle intervention on body weight and physical activity in patients with breast cancer can reduce the risk of death in obese women: The EMILI study	308
Hereditary ovarian cancers: State of the art	275
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials	260
PARP inhibitors for the treatment of ovarian cancer	211
Totale	1.737

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	107	0	0	3	11	3	13	2	4	14	16	28	13
2022/2023	162	16	26	9	19	12	22	2	12	31	3	4	6
2023/2024	83	2	3	6	15	21	6	9	5	0	4	4	8
2024/2025	297	7	0	4	17	59	43	29	18	49	13	21	37
2025/2026	590	33	4	37	58	76	41	66	33	42	63	70	67
2026/2027	76	22	44	10	0	0	0	0	0	0	0	0	0
Totale													1.737